Search
Puma Biotechnology Inc
PBYIAdd to Watchlist
7.930USD
+0.040+0.51%
Close 07-31 16:00（ET）Quotes delayed by 15 min
403.63MMarket Cap
16.24P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Puma Biotechnology Inc is 6.00, ranking 132 out of 155 in the Pharmaceuticals industry. The average price target is 5.00, with a high of 7.00 and a low of 2.00.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
5.000
Target Price
-36.95%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Puma Biotechnology Inc
PBYI
1
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Puma Biotechnology Inc's expected revenue for the next quarter?
Puma Biotechnology Inc's expected revenue is 53.00M.
What is Puma Biotechnology Inc's price target?
Analysts forecast that Puma Biotechnology Inc's price target is USD 5.00, with the highest forecast at USD 7.00 and the lowest forecast at USD 2.00.
How have Puma Biotechnology IncPBYI's recent earnings per share performed?
The market expectation was USD -0.07, while Puma Biotechnology IncPBYI's earnings per share (EPS) for the previous quarter was USD 0.27. EPS for the next quarter is expected at USD 0.04.
What is the analyst rating for Puma Biotechnology Inc?
Based on the ratings of Puma Biotechnology Inc's stock from 1 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.